Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry

Autor: Marita Knudsen Pope, Dan Atar, Arne Svilaas, Torstein Hole, Jørn Dalsgaard Nielsen, Ulrik Hintze, Milita Crisby, Pekka Raatikainen, K. E. Juhani Airaksinen, Saverio Virdone, Karen Pieper, Gloria Kayani, Jean-Yves Le Heuzey, Jan Steffel, Janina Stepinska, Jean-Pierre Bassand, A. John Camm
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Annals of Medicine, Vol 53, Iss 1, Pp 485-494 (2021)
Druh dokumentu: article
ISSN: 07853890
1365-2060
0785-3890
DOI: 10.1080/07853890.2021.1893897
Popis: AbstractAims The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries.Methods We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries.Results A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0–1 (72.8% vs 60.3%), 2–3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11–4.23) vs 4.08 (3.91–4.26), p value = .147] and [0.98 (0.73–1.32) vs 1.02 (0.93–1.11), p value = .819], while major bleeding was significantly higher [1.66 (1.32–2.09) vs 1.01 (0.93–1.10), p value
Databáze: Directory of Open Access Journals
Externí odkaz: